| Name | Title | Contact Details |
|---|
Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of prescription medicines for pets in the United States and Europe. It develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a potent and selective ghrelin agonist for the stimulation of appetite in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension to manage post-operative pain in cats and dogs following surgery. The company was founded in 2010 and is headquartered in Kansas City, Kansas.
Alzheimer's Association is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Broen Memorial Home is a Fergus Falls, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
Genetic Technologies, Inc. is an independent, full service and multi-accredited DNA forensic science company focusing primarily on the testing and evaluation of forensic evidence as it relates to human identification. Established in 1998, Genetic Technologies, Inc. serves a rapidly growing nationwide and worldwide customer base of private citizens, investigators, law enforcement agencies, public defenders, criminal defense attorneys, and prosecutors. We offer our clients access to a broad range of forensic biology technologies—specializing in DNA analysis, (Autosomal and Y-STRs), touch DNA (Low Copy Analysis), Crime Scene Investigation (CSI), serology, and expert witness & consulting services for civil investigations / criminal prosecution & defense. Our forensic division has played a pivotal role in a hundreds of high profile criminal cases with our civil and relatedness divisions assisting clients in thousands of immigration / relatedness DNA tests including a wide spectrum of infidelity scenarios. Our seasoned staff of expert scientists utilizes the most advanced methodologies available to detect and test DNA from many sources. We offer fast, accurate and personalized service for each of our customers, including consulting and expert witness services in conjunction with forensic testing. Genetic Technologies, Inc. is a leader in the Forensic Science and Human Identification Industry and provides specialized software to the eDNA Consortium. eDNA is a software developed by Genetic Technologies, Inc. which is used by many facilities in the Human Identification Industry.